Hermann M - Search Results

1

Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice.

Quaschning T, Ruschitzka F, Stallmach T, Shaw S, Morawietz H, Goettsch W, Hermann M, Slowinski T, Theuring F, Hocher B, Lüscher TF, Gassmann M. Quaschning T, et al. Among authors: hermann m. FASEB J. 2003 Feb;17(2):259-61. doi: 10.1096/fj.02-0296fje. Epub 2002 Dec 18. FASEB J. 2003. PMID: 12490547

2

Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.

Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Lüscher TF, Ruschitzka F. Hermann M, et al. Circulation. 2003 Nov 11;108(19):2308-11. doi: 10.1161/01.CIR.0000101683.30157.0B. Epub 2003 Nov 3. Circulation. 2003. PMID: 14597594

3

Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2.

Hermann M, Enseleit F, Ruschitzka FT. Hermann M, et al. Curr Hypertens Rep. 2005 Feb;7(1):52-60. doi: 10.1007/s11906-005-0055-7. Curr Hypertens Rep. 2005. PMID: 15683587 Review.

4

Nitric oxide in hypertension.

Hermann M, Flammer A, Lüscher TF. Hermann M, et al. J Clin Hypertens (Greenwich). 2006 Dec;8(12 Suppl 4):17-29. doi: 10.1111/j.1524-6175.2006.06032.x. J Clin Hypertens (Greenwich). 2006. PMID: 17170603 Free PMC article. Review.

5

Endothelin-receptor antagonists in arterial hypertension: further indications?

Sudano I, Hermann M, Ruschitzka FT. Sudano I, et al. Among authors: hermann m. Curr Hypertens Rep. 2007 Mar;9(1):59-65. doi: 10.1007/s11906-007-0011-9. Curr Hypertens Rep. 2007. PMID: 17362673 Review.

6

Constitutively overexpressed erythropoietin reduces infarct size in a mouse model of permanent coronary artery ligation.

Camici GG, Stallmach T, Hermann M, Hassink R, Doevendans P, Grenacher B, Hirschy A, Vogel J, Lüscher TF, Ruschitzka F, Gassmann M. Camici GG, et al. Among authors: hermann m. Methods Enzymol. 2007;435:147-55. doi: 10.1016/S0076-6879(07)35008-8. Methods Enzymol. 2007. PMID: 17998053

7

The hypertension peril: lessons from CETP inhibitors.

Hermann M, Ruschitzka FT. Hermann M, et al. Curr Hypertens Rep. 2009 Feb;11(1):76-80. doi: 10.1007/s11906-009-0014-9. Curr Hypertens Rep. 2009. PMID: 19146805 Review.

8

Torcetrapib impairs endothelial function in hypertension.

Simic B, Hermann M, Shaw SG, Bigler L, Stalder U, Dörries C, Besler C, Lüscher TF, Ruschitzka F. Simic B, et al. Among authors: hermann m. Eur Heart J. 2012 Jul;33(13):1615-24. doi: 10.1093/eurheartj/ehr348. Epub 2011 Sep 14. Eur Heart J. 2012. PMID: 21920972 Free article.

9

Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension.

Hermann M, Shaw S, Kiss E, Camici G, Bühler N, Chenevard R, Lüscher TF, Gröne HJ, Ruschitzka F. Hermann M, et al. Hypertension. 2005 Feb;45(2):193-7. doi: 10.1161/01.HYP.0000153053.82032.bf. Epub 2005 Jan 3. Hypertension. 2005. PMID: 15630049 Free article.

10

Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation.

Steffel J, Hermann M, Greutert H, Gay S, Lüscher TF, Ruschitzka F, Tanner FC. Steffel J, et al. Among authors: hermann m. Circulation. 2005 Apr 5;111(13):1685-9. doi: 10.1161/01.CIR.0000160358.63804.C9. Epub 2005 Mar 28. Circulation. 2005. PMID: 15795326

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

891 results

Search Page

Filters